Stocks / NASDAQ / Polaryx Therapeutics Inc.

Polaryx Therapeutics Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: PLYX – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Polaryx Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated on its website that they exploit animals for drug testing.

“PLX-400 is a preclinical stage novel gene therapy candidate. It is designed to deliver lysosomal genes in appropriate adeno-associated viral vectors. Initial development of PLX-400 is focused on the treatment of CLN2 and CLN3, and additional preclinical animal studies are ongoing with the goal of advancing the program toward clinical development.” Read the following article

Company Description

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Company Website: https://www.polaryx.com

Contact: info@polaryx.com